SAGE 217

Drug Profile

SAGE 217

Alternative Names: SAGE217

Latest Information Update: 28 Dec 2016

Price : $50

At a glance

  • Originator SAGE Therapeutics
  • Class Antiepileptic drugs; Small molecules; Steroids
  • Mechanism of Action GABA A receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes - Seizures

Highest Development Phases

  • Phase II Essential tremor; Major depressive disorder; Parkinson's disease; Postnatal depression
  • Phase I Seizures

Most Recent Events

  • 19 Dec 2016 Phase-II clinical trials in Postnatal depression in USA (unspecified route)
  • 13 Dec 2016 Phase-II clinical trials in Essential tremor in USA (PO) , NCT02978781)
  • 13 Dec 2016 Phase-II clinical trials in Parkinson's disease in USA (PO) (NCT03000569,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top